Capsugel Buys Encap as Part of Dosage Form Solution Strategy

Capsugel Buys Encap Drug Delivery

Capsugel says the acquisition of Encap is part of its recently announced Dosage Form Solutions (DFS) strategy.

The purchase of Encap Drug Delivery is another development in a currently dynamic marketplace, with Capsugel benefitting from the Scottish CDMO’s lipid-based formulation expertise and the world’s largest liquid and semi-solid filled capsule facility.

“This acquisition will accelerate the strategy laid down in the recently announced formation of the DFS Business Unit,” President of the unit Amit Patel told in-Pharmatechnologist.com.

He added, “Encap adds important value to Capsugel as a whole,” giving the company “access to technology platforms, development capabilities, and manufacturing infrastructure – including a fully accredited [US] FDA and MHRA facility.”

The cGMP manufacturing facility in Livingston, UK includes 15,000 square feet of clean room area and a dedicated high containment suite as well as manufacturing equipment capable of batch sizes of up to 100m capsules.

According to Patel, it will be business as usual at the facility with Capsugel keeping all current contracts and personnel. However, the “site is not yet fully utilized” and there “is room to expand and grow within the current infrastructure” as part of the DFS Unit.

Capsugel will also acquire Encap’s R&D intellectual property and technology platforms including DuoCap and ENCODE, two targeted release technologies which complement its offerings as the company develops products to improve bioavailability, absorption, ability to stabilize, ability to optimize and behavior of products.

Financial details of the deal have not been disclosed.

More Acquisitions in the Pipeline?

The Capsugel-Encap deal is the second major takeover announced in the oral dose drug delivery sector in as many months, following Mitsubishi Chemical Holdings purchase of global HPMC and gelatin capsule company Qualicaps. Furthermore, back in October, Patheon entered the softgel market with its acquisition of Banner Pharmacaps.

In-Pharmatechnolgy.com asked Patel whether recent acquisitions were due to any specific factor and what direction the industry is moving in.

“Regarding the industry as a whole, each acquisition has its own driving thesis,” he said adding that these big deals should not affect competitiveness or quality of the product. “When the right companies join forces, whether through mergers or partnerships, the customer can benefit in the form of better products and services.”

Patel continued to say that he expects that there will be further deals and Capsugel itself will continue to look and consider further acquisitions in both its DFS and hard capsules business areas.

Related News

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel Launches Lipidex Encapsulating Platform from New DFS Unit

Capsugel Launches Lipidex Encapsulating Platform from New Dosage Form Unit

Medicago shareholders OK Mitsubishi takeover

Mitsubishi Closer to Buying Vax and Biosimilar Tech Developer Medicago

Three Capsugel plants have seen recent expansions

Capsugel expands manufacturing capacity at three FDF plants

Catalent purchases Brazilian softgel firm Relthy Labs

Catalent's Brazilian acquisition supports global softgel strategy

Capsugel and Bend begin tech transfer following takeover

Capsugel and Bend: 'Marriage made in heaven' as first tech transferred

Capsugel: 'More than a capsule maker,' as it wins manufacturing contract

'No longer simply a capsule provider' - Capsugel wins oral peptide contract

Capsugel is formulating biotherapeutics to be delivered into the lungs

Capsugel focusing on inhaled biotherapeutics from Bend facility

The facility in Ediburgh, Scotland was acquired when Capsugel bought Encap in 2013

Capsugel expanding Encap plant on rising HPAPI demand

Capsugel announce new dosage form business unit

Capsugel Launches New Oral Formulation Business Unit

Encap lands long-term manufacturing contract

Encap lands long-term manufacturing contract

Capsugel expands liquid fill capsule capabilities

Patheon to buy Banner for softgel caps

Patheon to buy Banner Pharmacaps for $255m

Mitsubishi to buy Qualicaps for $654m

Mitsubishi to buy dominant HPMC capsule maker Qualicaps as gelatin shortages continue

Qualicaps expand oral dose manufacture: competition heats up

Oral Dose Competition Intensifies as Qualicaps Expands Manufacturing

Related Products

See more related products